AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00750269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 55.0 Gy
Description: SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy
Study NCT00750269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 57.5 Gy
Description: SBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy
Study NCT00750269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 60.0 Gy
Description: SBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy
Study NCT04326374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon hGH
Description: Once weekly subcutaneous injection
Study NCT04326374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daily hGH
Description: Once daily subcutaneous injection
Study NCT04555447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agavins (prebiotic fiber)
Description: Agavins contained in ready-to-use sachets were dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
Study NCT01612832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
Study NCT01612832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: pain treatment as customary in the department
Study NCT04555447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin contained in ready-to-use sachets was dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
Study NCT03069664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: endoscopic retrograde cholangiopancreatography
Study NCT03069664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covered Self-expandable Metal Stent
Description: Pancreatic duct stent
Study NCT04706377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B12 fix 1000mcg
Description: oral dispersible tablet with vitamin B12 1000mcg
Study NCT00923611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Study NCT00923611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fimasartan
Study NCT04276376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w
Study NCT04706377 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT04276376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID
Study NCT03193827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-line filtration
Description: In-line filtration is used during anesthesia and postoperative 96 hrs in study group to purify endovascular fluids administrations reducing postoperative phlebitis
Study NCT03193827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Patients are treated with standard intravenous solutions and vascular access management
Study NCT02874703 — intervention group
Intervention type: OTHER
Intervention: Cardiac MRI/MRS
Study NCT02067676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsule-Conjugate Campylobacter Vaccine (CJCV1)
Description: The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)
Study NCT02067676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alhydrogel®, aluminum hydroxide adjuvant (alum)
Study NCT03746119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette vapor containing nicotine
Description: A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed e-solution containing nicotine.
Study NCT03746119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette vapor, nicotine free
Description: A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed nicotine free e-solution.
Study NCT03159039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Study NCT03159039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged slow exhalation technique
Description: Postural drainage associated with manual vibration and a mild pressure in the end of expiratory phase
Study NCT03276091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colofit+ intervention
Description: Personnalized phone call, done by the medical student in the name of Adémas-69, organized cancers screening in the Rhône area association. This is a motivational call to encourage patients with an immunochemical fecal test positive, to realized their colonoscopy.
Study NCT04153552 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: HLNatural, Inc. Upset Stomach Relief
Description: Supplement to take with mild to moderate indigestion. The degree of your indigestion pre and post will be recorded
Study NCT01553370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Increased Dairy Intake
Description: 3 additional servings of low fat dairy will be consumed
Study NCT01553370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased Dairy Intake
Description: 3 additional servings of low fat dairy will be consumed
Study NCT01553370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental carbohydrate
Description: Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV
Study NCT00720109 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Some patients undergo cranial RT
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02189135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: The glucometer acts by automatically uploading any glucose readings to an online portal. A summary of the patient's glycaemic and metabolic control, self-management skills as well as compliance to other key measures such as eye examination, screening for microvascular complications would also be provided if available. All patients in this intervention arm would be given a system-driven guidance on when to test their blood glucose based on their disease status, medication regimen, and time of poorest control so that the most useful, patient specific blood profile can be created and used for future self-management coaching for patient
Study NCT01553370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental carbohydrate
Description: Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
Study NCT02313961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Description: Remote ischaemic conditioning is induced by 3 cycles of manual inflation of a blood pressure cuff placed on the left lower limb to 200 mmHg for 5 minutes and then deflation to 0 mmHg for another 5 minutes.
Study NCT04162860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eso-SPONGE® device
Description: Preemptive ENP therapy will be carried out with either an Eso-SPONGE® device system (Eso-SPONGE®, B. Braun Melsungen AG, Melsungen, Germany). Eso-SPONGE® consists of an open-pored polyurethane foam fitted to a gastric tube. Secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg.
Study NCT03595553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridinilazole
Description: ridinilazole (200 mg bid)
Study NCT02181725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Rehabilitation Program
Description: The Multimodal Rehabilitation Program is a Graded exposure based treatment. It consists of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM).
Study NCT02181725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual
Description: Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
Study NCT02895867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full fat dairy
Description: Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
Study NCT03595553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: vancomycin (125 mg qid)
Study NCT02238444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
Study NCT02238444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
Study NCT02238444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
Study NCT02238444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
Study NCT02238444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparin
Description: From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Study NCT02238444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin
Description: From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Study NCT00782769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutinyn Vaginal Ring 4mg
Study NCT02895867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat dairy
Description: Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
Study NCT02895867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
Study NCT04165421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family intervention group
Description: Education and Family conversations
Study NCT03186352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photoactivated disinfection
Description: After manual preparation of the cavity with an excavator and taking a sample for a microbial analysis with a rose bur on micro motor (size 014) the cavity undergoes the procedure of photodynamic disinfection:~application of photosensitizer 'Fotosan' Agent (CMS Dental, Denmark) for 5 minutes, radiation with low power laser, wavelength 635 nm power 200mW 120 s. ('Lasotronix', DiodeLX model SMART) rinsing with water and drying
Study NCT00324961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adefovir dipivoxil tablets
Description: adefovir dipivoxil once daily 10 mg orally
Study NCT03899467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT0918
Description: anti-tumor activity
Study NCT00542308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Individual dose titration weekly i.v. doses
Study NCT01386866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of \[14C\]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
Study NCT03181256 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of sputum
Study NCT03181256 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen collection
Description: Undergo collection of nasal epithelium
Study NCT03181256 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen collection
Description: Undergo collection of buccal epithelium
Study NCT03181256 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen collection
Description: Undergo collection of blood
Study NCT03181256 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen collection
Description: Undergo collection of urine
Study NCT03181256 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary Function Test
Description: Undergo pulmonary function test
Study NCT03181256 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography (CT)
Description: Undergo chest CT
Study NCT03181256 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker
Description: Correlative studies
Study NCT00782769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutinyn Vaginal Ring 6mg
Study NCT03954535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free2b
Description: The intervention will consist of a website and 9 sessions. The intervention sessions will facilitate youths' acquisition of personal and social cognitive-behavioral skills. The intervention will focus on goal setting, decision making, enhancing self-worth, coping with stress, combating distorted thinking, communication skills, using alcohol and other drugs and a review session. Each session will require approximately 20 minutes and must be finished in a single sitting. Sessions will be delivered on a weekly basis. The website will include entertainment features and resources.
Study NCT03954535 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-Placebo
Description: Access to the website with entertainment features and resources - but no session content.
Study NCT01440621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up
Study NCT01440621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pyridoxine
Description: Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
Study NCT00903175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
Study NCT03028454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger Root
Description: Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.
Study NCT03028454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing rice flour powder.
Study NCT00968513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: (N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization
Study NCT00968513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Treatment
Description: (N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
Study NCT00968513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
Study NCT02640508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
Study NCT02640508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Will be taken orally at 20-24 mg daily in each 21 day cycle.
Study NCT03506893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alphapump
Description: Alfapump® device: a completely internalized medical device, implanted under the skin, which mobilizes ascites from the peritoneal cavity to the bladder where they are eliminated by the urinary tract.~Medical device marked CE, used in the indication provided for marking
Study NCT00085735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given orally
Study NCT03506893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ascites puncture
Description: Hospitalizations for evacuating ascites are performed at least twice a month and can be up to 2 times a week. A clinical and biological examination is carried out at each visit.
Study NCT00223080 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV vCP1521 + AIDSVAX
Description: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL
Study NCT00223080 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC Placebo + AIDSVAX Placebo
Description: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection
Study NCT04343235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: five day course of furosemide 20mg QD
Study NCT04343235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: labetalol
Description: 200mg labetalol BID
Study NCT04343235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: labetalol
Description: 200mg labetalol BID
Study NCT03237286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Description: Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
Study NCT03237286 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous ketamine
Description: Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
Study NCT03237286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based Cognitive Training
Description: Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression.
Study NCT03237286 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer-based Cognitive Training
Description: Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression.
Study NCT01763996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat capsules
Study NCT01763996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat placebo
Description: Febuxostat placebo-matching capsules
Study NCT00903175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
Study NCT00903175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
Study NCT00903175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib
Description: Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.